BIAFW BIOAFFINITY TECHNOLOGIES INC C/WTS 12/08/2027 (TO PUR COM)
- 0.300
- -0.104-25.69%
8-K: Current report
424B3: Prospectus
EFFECT: Others
S-1: General form for registration of securities under the Securities Act of 1933
424B3: Prospectus
424B3: Prospectus
DEF 14A: Definitive information statements
10-Q: Q3 2024 Earnings Report
8-K: bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
PRE 14A: Preliminary proxy statements relating to merger or acquisition
4: Statement of changes in beneficial ownership of securities-Officer Edwards James Michael
D: Filing D
424B5: Prospectus
8-K: Securities Purchase Agreement
8-K: bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
8-K: bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
8-K: Poll Results of 2024 Extraordinary General Meeting
424B3: Prospectus
3: Initial statement of beneficial ownership of securities-Officer Edwards James Michael
EFFECT: Others